PEGylation of Interferon-β-1a

@article{Kieseier2012PEGylationOI,
  title={PEGylation of Interferon-β-1a},
  author={B. Kieseier and P. Calabresi},
  journal={CNS Drugs},
  year={2012},
  volume={26},
  pages={205-214}
}
  • B. Kieseier, P. Calabresi
  • Published 2012
  • Medicine
  • CNS Drugs
    • Achieving optimal patient benefit from biological therapies can be hindered by drug instability, rapid clearance requiring frequent dosing or potential immune reactions. One strategy for addressing these challenges is drug modification through PEGylation, a well established process by which one or more molecules of polyethylene glycol (PEG) are covalently attached to a biological or small-molecule drug, effectively transforming it into a therapy with improved pharmacokinetic and pharmacodynamic… CONTINUE READING
    View on Springer
    ncbi.nlm.nih.gov
    42 Citations
    Background Citations
    6
    Methods Citations
    1
    Results Citations
    1

    Figures, Tables, and Topics from this paper

    Figures and Tables

    Explore Further: Topics Discussed in This Paper

    42 Citations
    Citation Type

    Citation Type

    An update on the evidence base for peginterferon β1a in the treatment of relapsing–remitting multiple sclerosis
    • 7
    Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial
    • 25
    COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects
    • 21
    Peginterferon beta-1a for the treatment of relapsing multiple sclerosis: A case series.
    • Barry Hendin
    • Medicine
    • Multiple sclerosis and related disorders
    • 2018
    • 1
    Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-Ia in Subjects with Normal or Impaired Renal Function
    • 3
    Peginterferon Beta-1a: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis
    • 14
    Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
    • 5
    • PDF
    Glycoengineering of Interferon-β 1a Improves Its Biophysical and Pharmacokinetic Properties
    • 27
    • PDF
    Peginterferon beta-1a in relapsing–remitting multiple sclerosis: a guide to its use in the EU
    • 1
    Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors?

    References

    SHOWING 1-10 OF 71 REFERENCES
    Pegylated IFNs for chronic hepatitis C: an update
    • 22
    Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients
    • 62
    Peginterferon alpha-2b: a new approach to improving response in hepatitis C patients
    • 13
    N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
    • 130
    Pegylated Interferons for the Treatment of Chronic Hepatitis C
    • 97
    Pegylation: a novel process for modifying pharmacokinetics.
    • 701
    PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis.
    • D. Baker, R. Pepinsky, +15 authors G. Davar
    • Medicine
    • Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
    • 2010
    • 32
    Nanomedicines in the treatment of chronic hepatitis C – focus on pegylated interferon alpha-2a
    • 11
    PEG conjugates in clinical development or use as anticancer agents: an overview.
    • 361
    Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma.
    • 15